mirikizumab (LY3074828) - Eli Lilly
Mirikizumab: Primary completion of P3 VIVID-1 trial (NCT03926130) for Crohn's disease in Feb 2022 (Eli Lilly) - Oct 23, 2019 - Q3 2019 Results: Completion of P3 VIVID-1 trial for Crohn's disease in Jul 2023; Completion of P3 OASIS-1 trial (NCT03482011) in moderate-to-severe plaque psoriasis in Feb 2020 
Trial completion date • Trial primary completion date
https://investor.lilly.com/static-files/c4eae44d-aea0-4f4b-90d9-d7e6d86412af
 
Oct 23, 2019
 
 
6f552085-6cef-45b1-adc6-edaeb5bac326.jpg